MARVIN MOSER; ANDREW G. PRANDONI, M.D.; JAMES A. ORBISON; THOMAS W. MATTINGLY
During the last five years numerous agents capable of blocking the sympathetic nervous system have been utilized in the study and treatment of peripheral vascular disease.1-8 Although these agents act in different ways and at different sites, the objective—a partial or complete blockade of the sympathetic nervous system—is the same. This "sympatholytic" effect may be produced by a substance which interferes with sympathetic vasoconstrictor reflexes through a central site of action,9, 10 or peripherally, by a drug which blocks sympathetic nerve activity at the neuroeffector junction11, 12 (figure 1). In addition to inhibiting the response to sympathetic nerve stimulation, an
MARVIN MOSER, ANDREW G. PRANDONI, JAMES A. ORBISON, THOMAS W. MATTINGLY. CLINICAL EXPERIENCE WITH SYMPATHETIC BLOCKING AGENTS IN PERIPHERAL VASCULAR DISEASE(CLINICAL EXPERIENCE WITH SYMPATHETIC BLOCKING AGENTS IN PERIPHERAL VASCULAR DISEASE*). Ann Intern Med. 1953;38:1245–1264. doi: 10.7326/0003-4819-38-6-1245
Download citation file:
Published: Ann Intern Med. 1953;38(6):1245-1264.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use